Skip to main content
main-content

20-06-2022 | EULAR 2022 | Conference coverage | Video

BE MOBILE 1 and 2: How might bimekizumab impact axSpA clinical practice?

share
SHARE

Fabian Proft discusses the potential impact of bimekizumab on the treatment of radiographic and nonradiographic axial spondyloarthritis in light of findings from the BE MOBILE 1 and 2 trials (3:02).

EULAR 2022 Congress coverage

Access the latest news and expert insight from the EULAR 2022 Congress.

New additions to the Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.